Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Shire receives FDA fast track designation for Replagal

Feb. 25, 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA for filing

Feb. 25, 2010

Amylin and Takeda to begin phase III trial of pramlintide/metreleptin in obesity

Feb. 23, 2010

Takeda and Affymax begin phase III trial of Hematide in chronic renal failure

Feb. 23, 2010

GSK and FDA present safety update on Avandia for type 2 diabetes

Feb. 23, 2010

BioSante reports phase III LibiGel safety data

Feb. 23, 2010

PPARdelta agonists discovered at sanofi-aventis

Feb. 23, 2010

EnzymeRx provides clinical update on pegsitacase

Feb. 23, 2010

FDA sets PDUFA action date for Amgen's complete response submission for Prolia

Feb. 22, 2010

Pivotal Research adds U.S. center to phase II study of VA-111913 for dysmenorrhea

Feb. 18, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...